Deborah Harland - Partner

Deborah joined SR One in 2005 and leads SR One's investment activities in Europe. She is currently a member of the Board of Directors of Protaffin AG, Syntaxin Limited, Bicycle Therapeutics Limited and f-star GmbH and is an observer on the board of 7TM Pharma. Deborah was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO on SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Board of Ablynx (IPO, Euronext Brussels 2007). Deborah has extensive drug development experience gained through the various roles she has held in clinical development, medical affairs and business development. Immediately prior to SR One, Deborah was part of GSK's Worldwide Business Development team where she evaluated in-licensing opportunities in the CNS and GI therapeutic areas. Deborah holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College
 
Aileron    Alios    Locus Pharmaceuticals